ReviewNature reviews. Disease primers2022
Large-vessel vasculitis.
Review in Nature reviews. Disease primers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 133 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
133 citing papers in PubMed, 3 syntheses or guidelines pooled it, 219 citations in OpenAlex.
- Cross-Trait Meta-Analysis Reveals a Genetic Link between Inflammation and Aging in Giant Cell Arteritis.Aging and disease · 2025Pooled it
- Systematic review and meta-analysis of the current literature on tocilizumab in patients with refractory Takayasu arteritis.Frontiers in immunology · 2023Pooled it
- Presentation and clinical course of pediatric-onset versus adult-onset Takayasu arteritis-a systematic review and meta-analysis.Clinical rheumatology · 2022Pooled it
- Baricitinib for Takayasu arteritis refractory to TNF-α inhibitors: a multicentre, single-arm trial.Rheumatology (Oxford, England) · 2025Trial
- Clinical experience and safety of Janus kinase inhibitors in giant cell arteritis: a retrospective case series from Sweden.Frontiers in immunology · 2023Trial
- [Management of emergencies in rheumatology].Zeitschrift fur Rheumatologie · 2026Review
- A case of Takayasu arteritis misdiagnosed as dilated cardiomyopathy: a case report.European heart journal. Case reports · 2026Article
- Beyond the dilated ventricle: the echocardiographer's role in interpreting the clues.European heart journal. Case reports · 2026Article
- Prognosis and Long-Term Outcome of Stenotic Large Vessel Involvement in Giant Cell Arteritis.Arthritis & rheumatology (Hoboken, N.J.) · 2026Article
- Quantitative imaging features of pulmonary artery involvement in Takayasu arteritis on computed tomography pulmonary angiography in patients with and without pulmonary hypertension.Quantitative imaging in medicine and surgery · 2026Article
- Vascular compliance phenotyping in pulmonary arterial hypertension (a PVDOMICS study).JHLT open · 2026Article
- Time to diagnosis in large vessel vasculitis: insights from a retrospective study at a tertiary rheumatology centre.RMD open · 2026Article
- Takayasu Arteritis and Giant Cell Arteritis: Results From a Cross-Sectional Study of 96 Italian Patients.Immunity, inflammation and disease · 2026Article
- Giant Cell Arteritis With Normal Inflammatory Markers and Progressive Visual Disturbance.Cureus · 2026Article
- Large vessel vasculitis reframed: integrating conceptual shifts and evidence into practice for Takayasu arteritis and giant cell arteritis.Journal of rheumatic diseases · 2026Review
- Challenges and Future Trends in Large Vessel Vasculitis.Circulation · 2026Review
- [Management of emergencies in rheumatology].Medizinische Klinik, Intensivmedizin und Notfallmedizin · 2026Review
- What Lies Beyond the Thyroid? A Case of Neck Pain, Fever, and Hypertension.Journal of general and family medicine · 2026Article
- Conceptual Reconsideration of the Classification of Pulmonary Hypertension: From 5 Groups to 2 Groups.JACC. Asia · 2026Review
- Spatially controlled tenascin-C accumulation contributes to inflammatory disease persistence in giant cell aortitis.JCI insight · 2026Article
73 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 8 institutions in 4 countries.
Funding
Abstract
Large-vessel vasculitis (LVV) manifests as inflammation of the aorta and its major branches and is the most common primary vasculitis in adults. LVV comprises two distinct conditions, giant cell arteritis and Takayasu arteritis, although the phenotypic spectrum of primary LVV is complex. Non-specific symptoms often predominate and so patients with LVV present to a range of health-care providers and settings. Rapid diagnosis, specialist referral and early treatment are key to good patient outcomes. Unfortunately, disease relapse remains common and chronic vascular complications are a source of considerable morbidity. Although accurate monitoring of disease activity is challenging, progress in vascular imaging techniques and the measurement of laboratory biomarkers may facilitate better matching of treatment intensity with disease activity. Further, advances in our understanding of disease pathophysiology have paved the way for novel biologic treatments that target important mediators of disease in both giant cell arteritis and Takayasu arteritis. This work has highlighted the substantial heterogeneity present within LVV and the importance of an individualized therapeutic approach. Future work will focus on understanding the mechanisms of persisting vascular inflammation, which will inform the development of increasingly sophisticated imaging technologies. Together, these will enable better disease prognostication, limit treatment-associated adverse effects, and facilitate targeted development and use of novel therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.